• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Does Maternal Hypothyroidism Increase the Risk for Childhood ADHD?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Peltier et al. (Am J Perinatol., 2020) examined whether hypothyroidism prior to, or during, pregnancy increases the risk of attention-deficit hyperactivity disorder (ADHD) in offspring

METHODS:

  • Retrospective cohort study (January 1, 2000 to December 31, 2016)
  • Population
    • Singleton births
  • Exposure
    • Maternal hypothyroidism: TSH >4.0 μIU/mL or fT4 ≤0.80 ng/dL
  • Study design
    • Data were abstracted from linked maternal–child medical records
    • Incidence rate differences (IRDs), adjusted hazard ratios (aHRs), and their 95% confidence intervals (CIs) were used to determine associations
    • Stratification based on timing of first diagnosis, gestational age at birth (term vs. preterm), sex, and race-ethnicity
    • Covariates: Child sex | Race-ethnicity | Maternal age | Education | Median family household income | Parity, and Timing of prenatal care | Smoking habits during pregnancy | Gestational age at delivery

RESULTS:

  • 329,157 births
  • Hypothyroidism diagnosed prior to, or during, pregnancy increases the risk of ADHD
    • Prior: IRD 1.30; aHR 1.27 (95% CI, 1.15 to 1.41)
    • During: IRD 0.59; 1.17 (95% CI, 1.00 to 1.38)
  • Association strongest when hypothyroidism was diagnosed during the first trimester
    • IRD 0.97; aHR 1.28 (95% CI, 1.04 to 1.58)
  • Preterm: Significantly increased risk of ADHD if mothers diagnosed prior to, but not during pregnancy
    • IRD 3.06; aHR 1.43 (95% CI ,1.09 to 1.88)
  • Association stronger for boys than for girls
    • Boys: IRD 1.84; aHR 1.26 (95% CI, 1.14 to 1.40)
    • Girls: IRD 0.48; aHR 1.19 (95% CI, 1.01 to 1.40)
  • Risk was also stronger for Hispanic children compares to other races or ethnicities
    • IRD 1.60; aHR = 1.45 (95% CI, 1.25 to 1.68)
  • Treatment effects
    • Maternal treatment with ≥50 μg/d thyroid supplementation was associated with increased risk for ADHD
    • aHR: 1.26 (95% CI, 1.14, 1.39)

CONCLUSION:

  • Children born to mothers diagnosed with hypothyroidism preconception or first trimester were at an increased risk for developing ADHD
  • Unclear if increased risk for ADHD in offspring treated with higher doses of thyroid supplementation is due to medication or more severe disease

Learn More – Primary Sources:

Maternal Hypothyroidism Increases the Risk of Attention-Deficit Hyperactivity Disorder in the Offspring

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Childhood Brain Development: Is There a Critical Window for Maternal TSH Measurement?
Are Thyroid Test Abnormalities a Risk Factor for Preterm Birth?
Could Smoking During Pregnancy Increase Risk for ADHD in Offspring?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site